Rating Change
JP Morgan reiterated its Overweight rating on Relay Therapeutics, Inc. (NASDAQ:RLAY) on August 14, 2026.
reiterateNASDAQ:RLAY
JP Morgan Reiterates Overweight Rating on Relay Therapeutics, Inc. (RLAY)
JP Morgan reiterated its Overweight rating on Relay Therapeutics, Inc. (NASDAQ:RLAY) on August 14, 2026.
At publication ·
What changed
Relay Therapeutics, Inc. (NASDAQ:RLAY) · reiterate
- Firm
- JP Morgan
- Rating
- Overweight to Overweight
- Price at event
- $19.86
- Market capitalization
- $1.4B
At a glance
Key takeaways
- JP Morgan reiterated an Overweight rating on Relay Therapeutics (RLAY) on August 14, 2026, with the stock trading at $19.86 and a market capitalization of $1.4 billion.
Market Context
Relay Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $19.86 with a market capitalization of $1.4B.
Analyst coverage from JP Morgan provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Relay Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Relay Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 14, 2026 | JP Morgan | Overweight | N/A |
| Aug 10, 2026 | Citizens | Market Outperform | N/A |
| Aug 07, 2026 | Barclays | Overweight | N/A |
| Jul 21, 2026 | Goldman Sachs | Buy | N/A |
| Jul 16, 2026 | Canaccord Genuity | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View RLAY Stock Page
Frequently Asked Questions
What does the Overweight rating mean for RLAY?
A rating of Overweight from JP Morgan reflects the analyst's outlook on Relay Therapeutics, Inc. (NASDAQ:RLAY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RLAY forecast page.